Rajka M. Liscic, Yuanhan Yang(?)

?

Biomarkers in Alzheimer’s disease

Rajka M. Liscic1,2, Yuanhan Yang3,4,5(?)

1Clinic for Neurology, RH?N Clinics, Campus Bad Neustadt, Bad Neustadt, Germany

2Department of Anatomy and Neuroscience, School of Medicine, University of Osijek, Osijek, Croatia

3Department of Neurology, Kaohsiung Municipal Ta‐Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China

4Department of Master’s Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China

5Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China

ARTICLE INFO

Received: 9 December 2015

Revised: 28 January 2016

? The authors 2016. This article is published with open access at www.TNCjournal.com

ABSTRACT

Alzheimer’s disease (AD) so far did not have promising treatment. The accurate and early diagnosis is still the important issue. For these purpose, biomarkers related to diagnosis, clinical course, and other aims have been proposed and reported. Meanwhile, along with the ongoing researches for AD, biomarkers with their own aims are also on the way.

KEYWORDS

Alzheimer’s disease; biomarker

Citation Liscic RM, Yang YH. Biomarkers in Alzheimer’s disease. Transl. Neurosci. Clin. 2016, 2(1): 1–2.

? Corresponding author: Yuanhan Yang, E-mail: endlessyhy@gmail.com

Dementia is a major global cause of disability and dependency worldwide. By 2030, the growing number of patients with dementia is estimated to reach 135.5 million to 2050. Much of the increase will be in the developing countries with the fastest growth in the elderly population. On the contrary, recent trends in dementia in several western countries, however, depict a gradual decline in prevalence and incidence. This decrease has been attributed to an improvement in education and living environments, engagement in healthy behaviors, and reduction in the prevalence of vascular risk factors[1]. On the contrary, in Asian countries, there is a stable trend of increase in dementia cases. People with dementia living in the developing countries account for 62% of all patients, but by 2050 this will rise to 71%. The total estimated global societal direct and indirect cost of global dementia in 2010 was $604 billion[2].

建筑群體的布置是否合理，對(duì)冬季獲得太陽(yáng)輻射熱和夏季通風(fēng)降溫非常重要。如建筑選址上，建筑用地不宜選擇在洼地、山谷等處，應(yīng)該選擇在向陽(yáng)、避風(fēng)的地段上，為建筑物爭(zhēng)取日照創(chuàng)造必要的條件。結(jié)合建筑用地的自然環(huán)境、氣候條件及建筑物的使用功能等，在不破壞原有生態(tài)環(huán)境的前提下，結(jié)合人的行為活動(dòng)特點(diǎn)，建立一個(gè)自然——人工生態(tài)平衡的系統(tǒng)，降低太陽(yáng)輻射、增強(qiáng)建筑物的通風(fēng)效果，利用建筑樓群的合理布局，在節(jié)約土地資源的前提下增加建筑物之間的間距，既爭(zhēng)取日照，又能合理組織氣流，從而使建筑物與空氣的熱交換增加，降低建筑能耗。

Alzheimer’s disease (AD) is a heterogeneous and slowly progressive illness characterized by extracellular amyloid‐β (Aβ) deposits and intracellular hyper‐phosphorylated tau protein aggregates. Aggregation of Aβ into oligomers, fibrils, and plaques is central in the molecular pathogenesis of AD. Although it is still unclear, multiple lines of evidence suggested that Aβ oligomers may be more toxic than fibrillary Aβ aggregates[3]. Accumulating evidence from studies on transgenic mouse models demonstrated that AD brain‐derived and synthetically prepared Aβ oligomers can cause early synaptic toxicity, long‐term potentiation (LTP) deficits, tau phosphorylation, and neurofibrillary tangles.

Biomarkers for the stratification, follow‐up, and monitoring of safe and effective therapeutic responses of Aβ disease‐modifying therapies (DMT) represent a research priority in this rapidly developing field. In particular, immunotherapy trials have underlined the urgent need of safety biomarkers to avoid, or at least enable the early detection of severe side effects of treatment termed amyloid‐related imaging abnor‐malities. The cerebrospinal fluid biomarkers Aβ, total tau, and hyperphosphorylated tau reflect the main pathological changes of AD with several novel biomarkers, such as, β‐site APP cleaving enzyme 1, soluble amyloid precursor proteins α and β, soluble Aβ oligomers, and others, which are associated with the occurrence and progression of this disease.

The main goal of research communities worldwide is to find several ideal biomarkers to improve the diagnosis of Alzheimer’s diseases, standardize biomarkers, and optimize the respective treatments. In addition to extracellular Aβ deposits, AD involves neurofibrillary tangles, another validated histopatholo‐gical feature, which consist of intracellular aggregates of hyperphosphorylated tau protein (p‐tau). Tau, a microtubule associated protein, participates in the microtubule stabilization and organization system, which regulates cellular morphogenesis, cytoskeleton functionality, and axonal transport. It is comprehensible that high levels of tau in the cerebrospinal fluid (CSF) of patients with AD can reflect the intensity of the neuronal damage and degeneration in the brain. The most commonly used measurement method for t‐tau and p‐tau is the enzyme‐linked immunosorbent assay (ELISA) using monoclonal antibodies that detect all isoforms of tau independently of phosphorylation state for t‐tau and antibodies that are specific for phosphorylation at either threonine181 (p‐tau181) or threonine231 (p‐tau231) for p‐tau. P‐tau231 is useful for distinguishing AD and frontotemporal dementia, and p‐tau181 can enhance classification between AD and dementia with Lewy bodies. Numerous studies have used this assay, and consistently report a pro‐minent increase in CSF total tau protein (t‐tau) and p‐tau in AD compared to control levels.

In order to provide more objective diagnosis, suitable radiotracers have been used over the past decades for imaging the Aβ aggregates[4]. For these purposes, neuroimaging techniques have been modified to achieve high specificity by using generated Aβ antibodies and peptide fragments that can be labeled with a suitable tracer[5]. The neuroimaging techniques are capable of detecting the amyloid plaques that are known to be formed several years prior to the actual manifestation of cognitive decline and amnesia that are characteristic of AD.

Briefly, biomarkers could be classified and used according to the requirements for evaluating therapy, clinical course, or some defined outcomes such as cog‐nitive outcome, behavior outcome, or socio‐economic outcomes. However, although many biomarkers have been proposed, the exact role of each biomarker should be fully understood before its application.

References

[1] Lee Y. The recent decline in prevalence of dementia in developed countries: Implications for prevention in the Republic of Korea. J Korean Med Sci 2014, 29(7): 913–918.

[2] Lublin AL, Gandy S. Amyloid-beta oligomers: Possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med 2010, 77(1): 43–49.

[3] Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW. Reversible in vitro growth of Alzheimer disease betaamyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992, 89(12): 5462–5466.

[4] Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002, 22(2): 223–231.

[5] Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52(8): 1210–1217.